UK Ebola patient discharged from hospital

2014-09-03 14:37

Multimedia   ·   User Galleries   ·   News in Pictures Send us your pictures  ·  Send us your stories

London - A British man who contracted Ebola in West Africa has been discharged after successful treatment with the experimental ZMapp drug, the Royal Free Hospital in London said on Wednesday.

William Pooley, 29, was treated in a special isolation unit after contracting the deadly disease in August when working as a volunteer nurse in Sierra Leone.

"Following 10 days of successful treatment in the high level isolation unit - the only one in the UK - Mr Pooley is being discharged from the Royal Free Hospital today," the hospital said in a statement on its website.

"He was flown to the hospital on Sunday 24 August 2014 and was treated with the experimental drug ZMapp," it added.

'I was very lucky in several ways'

Pooley later told reporters at a news conference he thought he had been fortunate.

"I was very lucky in several ways," he said. "Firstly in the standard of care that I received, which is a world apart from what people are receiving in West Africa at the moment despite lot of organisations' best efforts.

"The other difference to a lot of Ebola cases [is] that my symptoms never progressed to the worst stages of the disease. I had some unpleasant symptoms but nothing compared to some of the worst of the disease."

Governments and aid organisations have scrambled to contain the disease, which according to the World Health Organisation (WHO) has killed more than 1 500 in West Africa since March.

Human safety trials

ZMapp is one of several treatments for Ebola under development. The drug, although never tested in humans, gained attention this summer when two American aid workers who contracted Ebola in Liberia were cured after receiving it.

ZMapp, which uses antibodies from tobacco plants, is made by the privately held Mapp Biopharmaceutical Inc, based in San Diego, California.

The US Department of Health and Human Services has said a federal contract worth up to $42.3m would help accelerate testing of the treatment.

It said Mapp would manufacture a small amount of ZMapp for early stage safety studies and animal studies needed to prove its effectiveness and safety in people.

Human safety trials are due to begin this week on a vaccine from GlaxoSmithKline Plc and later this year on one from NewLink Genetics Corporation.

Read more on:    who  |  sierra leone  |  health  |  west africa  |  ebola

Join the conversation! encourages commentary submitted via MyNews24. Contributions of 200 words or more will be considered for publication.

We reserve editorial discretion to decide what will be published.
Read our comments policy for guidelines on contributions.
NEXT ON NEWS24X publishes all comments posted on articles provided that they adhere to our Comments Policy. Should you wish to report a comment for editorial review, please do so by clicking the 'Report Comment' button to the right of each comment.

Comment on this story
Comments have been closed for this article.

Inside News24


Book flights

Compare, Book, Fly

Traffic Alerts
There are new stories on the homepage. Click here to see them.


Create Profile

Creating your profile will enable you to submit photos and stories to get published on News24.

Please provide a username for your profile page:

This username must be unique, cannot be edited and will be used in the URL to your profile page across the entire network.


Location Settings

News24 allows you to edit the display of certain components based on a location. If you wish to personalise the page based on your preferences, please select a location for each component and click "Submit" in order for the changes to take affect.

Facebook Sign-In

Hi News addict,

Join the News24 Community to be involved in breaking the news.

Log in with Facebook to comment and personalise news, weather and listings.